Terms: = Gastric cancer AND NT5C2, ENSG00000076685, 22978, P49902, PNT5, NT5B, GMP, cN-II AND Prognosis
4 results:
1. cGAS regulates the DNA damage response to maintain proliferative signaling in gastric cancer cells.
Liu B; Liu H; Ren F; Liu H; Bukhari I; Fu Y; Wu W; Zhao M; Zhu S; Mo H; Li F; Zheng MB; Tang Y; Zheng P; Mi Y
Oncol Res; 2021; 29(2):87-103. PubMed ID: 37305397
[TBL] [Abstract] [Full Text] [Related]
2. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the prognosis of Epstein-Barr Virus-Associated gastric cancers.
Sun Q; Fu Y; Chen X; Li L; Wu H; Liu Y; Xu H; Zhou G; Fan X; Xia H
Gut Liver; 2022 Nov; 16(6):875-891. PubMed ID: 35611665
[TBL] [Abstract] [Full Text] [Related]
4. Identification and validation of the prognostic value of cyclic gmp-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
Yang KS; Xu CQ; Lv J
Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
[TBL] [Abstract] [Full Text] [Related]
